Advisory Research’s Ventyx Biosciences VTYX Stock Holding History

Advisory Research’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,507	Closed	-$1.02M	–	495
2023 Q1	$1.02M	Sell	30,507 -3,093	-9%	-$120K	0.17%	151
2022 Q4	$1.1M	Buy	33,600 +1,874	+6%	+$55.5K	0.1%	150
2022 Q3	$1.11M	Buy	+31,726	New	+$702K	0.11%	148

Other funds holding VTYX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Advisory Research's VTYX Position: Q2 2023 in Review

Advisory Research sold out of Ventyx Biosciences (VTYX) in Q2 2023, closing a stake of 30,507 shares — an estimated $1.02M sold.

Advisory Research first reported a position in VTYX in Q3 2022 and held it in 3 quarters. The position peaked at $1.11M in Q3 2022. 150 funds tracked by Wall St. Rank hold VTYX as of Q2 2023.

Advisory Research reported no remaining Ventyx Biosciences position as of Q2 2023 after selling out during the quarter.
Advisory Research sold 30,507 Ventyx Biosciences shares in Q2 2023, an estimated $1.02M.
Advisory Research first reported a position in Ventyx Biosciences in Q3 2022 and held it in 3 quarters.
Advisory Research's Ventyx Biosciences position peaked at $1.11M in Q3 2022.
150 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.